|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBE2V1 |
Gene summary for UBE2V1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBE2V1 | Gene ID | 7335 |
| Gene name | ubiquitin conjugating enzyme E2 V1 | |
| Gene Alias | CIR1 | |
| Cytomap | 20q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q13404 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7335 | UBE2V1 | sample3 | Human | Cervix | CC | 4.88e-22 | 4.05e-01 | 0.1387 |
| 7335 | UBE2V1 | H2 | Human | Cervix | HSIL_HPV | 5.00e-22 | 5.22e-01 | 0.0632 |
| 7335 | UBE2V1 | L1 | Human | Cervix | CC | 3.15e-04 | 4.42e-01 | 0.0802 |
| 7335 | UBE2V1 | T1 | Human | Cervix | CC | 1.05e-04 | 2.80e-01 | 0.0918 |
| 7335 | UBE2V1 | T2 | Human | Cervix | CC | 1.08e-04 | 4.26e-01 | 0.0709 |
| 7335 | UBE2V1 | T3 | Human | Cervix | CC | 4.80e-25 | 4.71e-01 | 0.1389 |
| 7335 | UBE2V1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.10e-20 | 3.81e-01 | 0.0155 |
| 7335 | UBE2V1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.09e-36 | 8.51e-01 | -0.1808 |
| 7335 | UBE2V1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.16e-29 | 8.76e-01 | -0.0811 |
| 7335 | UBE2V1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.84e-36 | 7.40e-01 | -0.1088 |
| 7335 | UBE2V1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.50e-55 | 8.60e-01 | -0.1954 |
| 7335 | UBE2V1 | HTA11_411_2000001011 | Human | Colorectum | SER | 6.46e-27 | 1.31e+00 | -0.2602 |
| 7335 | UBE2V1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.77e-16 | 7.74e-01 | -0.2196 |
| 7335 | UBE2V1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 9.27e-16 | 4.47e-01 | -0.1207 |
| 7335 | UBE2V1 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.06e-19 | 5.85e-01 | -0.1526 |
| 7335 | UBE2V1 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.28e-34 | 6.16e-01 | -0.1464 |
| 7335 | UBE2V1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.12e-29 | 5.11e-01 | -0.1001 |
| 7335 | UBE2V1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.33e-38 | 8.49e-01 | -0.059 |
| 7335 | UBE2V1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.27e-18 | 8.16e-01 | -0.1706 |
| 7335 | UBE2V1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.59e-17 | 6.36e-01 | -0.2061 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00431239 | Prostate | BPH | positive regulation of I-kappaB kinase/NF-kappaB signaling | 54/3107 | 186/18723 | 1.50e-05 | 1.92e-04 | 54 |
| GO:00002099 | Prostate | BPH | protein polyubiquitination | 64/3107 | 236/18723 | 2.83e-05 | 3.31e-04 | 64 |
| GO:200102015 | Prostate | BPH | regulation of response to DNA damage stimulus | 60/3107 | 219/18723 | 3.58e-05 | 3.92e-04 | 60 |
| GO:00510529 | Prostate | BPH | regulation of DNA metabolic process | 89/3107 | 359/18723 | 4.07e-05 | 4.36e-04 | 89 |
| GO:00510906 | Prostate | BPH | regulation of DNA-binding transcription factor activity | 100/3107 | 440/18723 | 4.71e-04 | 3.37e-03 | 100 |
| GO:00510924 | Prostate | BPH | positive regulation of NF-kappaB transcription factor activity | 40/3107 | 152/18723 | 1.54e-03 | 9.08e-03 | 40 |
| GO:00510916 | Prostate | BPH | positive regulation of DNA-binding transcription factor activity | 62/3107 | 260/18723 | 1.58e-03 | 9.23e-03 | 62 |
| GO:000724916 | Prostate | Tumor | I-kappaB kinase/NF-kappaB signaling | 77/3246 | 281/18723 | 1.55e-05 | 2.09e-04 | 77 |
| GO:004312217 | Prostate | Tumor | regulation of I-kappaB kinase/NF-kappaB signaling | 69/3246 | 249/18723 | 2.83e-05 | 3.43e-04 | 69 |
| GO:004312315 | Prostate | Tumor | positive regulation of I-kappaB kinase/NF-kappaB signaling | 53/3246 | 186/18723 | 1.04e-04 | 1.00e-03 | 53 |
| GO:000020914 | Prostate | Tumor | protein polyubiquitination | 64/3246 | 236/18723 | 1.08e-04 | 1.03e-03 | 64 |
| GO:200102016 | Prostate | Tumor | regulation of response to DNA damage stimulus | 59/3246 | 219/18723 | 2.37e-04 | 2.01e-03 | 59 |
| GO:005109014 | Prostate | Tumor | regulation of DNA-binding transcription factor activity | 105/3246 | 440/18723 | 2.69e-04 | 2.23e-03 | 105 |
| GO:005105212 | Prostate | Tumor | regulation of DNA metabolic process | 88/3246 | 359/18723 | 3.23e-04 | 2.59e-03 | 88 |
| GO:005109113 | Prostate | Tumor | positive regulation of DNA-binding transcription factor activity | 64/3246 | 260/18723 | 1.76e-03 | 1.04e-02 | 64 |
| GO:005109212 | Prostate | Tumor | positive regulation of NF-kappaB transcription factor activity | 39/3246 | 152/18723 | 6.15e-03 | 2.85e-02 | 39 |
| GO:005105216 | Skin | AK | regulation of DNA metabolic process | 60/1910 | 359/18723 | 8.56e-05 | 1.17e-03 | 60 |
| GO:200102020 | Skin | AK | regulation of response to DNA damage stimulus | 40/1910 | 219/18723 | 1.93e-04 | 2.19e-03 | 40 |
| GO:000020918 | Skin | AK | protein polyubiquitination | 41/1910 | 236/18723 | 4.78e-04 | 4.44e-03 | 41 |
| GO:004312224 | Skin | AK | regulation of I-kappaB kinase/NF-kappaB signaling | 42/1910 | 249/18723 | 7.65e-04 | 6.39e-03 | 42 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa051315 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa051316 | Colorectum | MSI-H | Shigellosis | 40/797 | 247/8465 | 4.28e-04 | 5.34e-03 | 4.47e-03 | 40 |
| hsa051317 | Colorectum | MSI-H | Shigellosis | 40/797 | 247/8465 | 4.28e-04 | 5.34e-03 | 4.47e-03 | 40 |
| hsa0513139 | Esophagus | HGIN | Shigellosis | 71/1383 | 247/8465 | 4.89e-07 | 7.98e-06 | 6.34e-06 | 71 |
| hsa05131114 | Esophagus | HGIN | Shigellosis | 71/1383 | 247/8465 | 4.89e-07 | 7.98e-06 | 6.34e-06 | 71 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0513128 | Prostate | BPH | Shigellosis | 94/1718 | 247/8465 | 5.19e-11 | 9.51e-10 | 5.89e-10 | 94 |
| hsa05131112 | Prostate | BPH | Shigellosis | 94/1718 | 247/8465 | 5.19e-11 | 9.51e-10 | 5.89e-10 | 94 |
| hsa0513129 | Prostate | Tumor | Shigellosis | 94/1791 | 247/8465 | 5.56e-10 | 9.69e-09 | 6.01e-09 | 94 |
| hsa0513137 | Prostate | Tumor | Shigellosis | 94/1791 | 247/8465 | 5.56e-10 | 9.69e-09 | 6.01e-09 | 94 |
| hsa0513112 | Stomach | GC | Shigellosis | 36/708 | 247/8465 | 6.74e-04 | 5.42e-03 | 3.82e-03 | 36 |
| hsa0513113 | Stomach | GC | Shigellosis | 36/708 | 247/8465 | 6.74e-04 | 5.42e-03 | 3.82e-03 | 36 |
| hsa0513141 | Stomach | CSG | Shigellosis | 34/633 | 247/8465 | 3.60e-04 | 3.25e-03 | 2.34e-03 | 34 |
| hsa0513151 | Stomach | CSG | Shigellosis | 34/633 | 247/8465 | 3.60e-04 | 3.25e-03 | 2.34e-03 | 34 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBE2V1 | SNV | Missense_Mutation | c.470N>C | p.Met157Thr | p.M157T | Q13404 | protein_coding | tolerated(0.12) | benign(0.04) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBE2V1 | SNV | Missense_Mutation | c.488N>T | p.Pro163Leu | p.P163L | Q13404 | protein_coding | deleterious(0.02) | possibly_damaging(0.469) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBE2V1 | SNV | Missense_Mutation | c.190G>A | p.Glu64Lys | p.E64K | Q13404 | protein_coding | deleterious(0.03) | benign(0.059) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| UBE2V1 | SNV | Missense_Mutation | c.113N>C | p.Phe38Ser | p.F38S | Q13404 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| UBE2V1 | SNV | Missense_Mutation | novel | c.356C>A | p.Ser119Tyr | p.S119Y | Q13404 | protein_coding | deleterious(0) | probably_damaging(0.918) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| UBE2V1 | SNV | Missense_Mutation | novel | c.445N>T | p.Arg149Cys | p.R149C | Q13404 | protein_coding | tolerated(0.12) | benign(0.041) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| UBE2V1 | SNV | Missense_Mutation | novel | c.76N>C | p.Lys26Gln | p.K26Q | Q13404 | protein_coding | deleterious_low_confidence(0.04) | benign(0.017) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBE2V1 | SNV | Missense_Mutation | c.190G>A | p.Glu64Lys | p.E64K | Q13404 | protein_coding | deleterious(0.03) | benign(0.059) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| UBE2V1 | SNV | Missense_Mutation | c.104N>A | p.Pro35His | p.P35H | Q13404 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A053-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBE2V1 | SNV | Missense_Mutation | c.190N>A | p.Glu64Lys | p.E64K | Q13404 | protein_coding | deleterious(0.03) | benign(0.059) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |